We are focused on bringing innovation to the treatment of cachexia and other muscle wasting conditions with a vision to transform care for an under-served and vulnerable patient population, prolong and improve the quality of their lives, restore their dignity and ease the burden for the patient, carer and provider.
NEWS
Jun 25, 2025
Actimed Therapeutics Enrols First Patients in Phase 2a PROACT Study Programme to Assess S-pindolol benzoate in Obese Patients During and Post-GLP-1 Agonist Therapy
May 20, 2025
Actimed Therapeutics Announces New Programme to Investigate Potential Muscle Preservation Effects of S-pindolol Benzoate in Obese Patients Treated with GLP-1 Agonists